SURMOUNT-OSA: Tirzepatide and obstructive sleep apnea The SURMOUNT-OSA trial (Malhotra et al., NEJM 2024, NEJMoa2404881, PMID 38912654) evaluated tirzepatide in adults with moderate to severe obstructive sleep apnea and obesity, in two parallel populations: subjects not receiving continuous positive airway pressure (CPAP) and subjects receiving CPAP at baseline
In addition, there are case reports that self-injecting peptides can lead to compartment syndrome, a painful buildup of pressure in a muscle
Morishita, R
Read More Partner Update | | 16 second read Maxwell Labs hosted an informational event for current and potential investors where they shared how their laser cooling technology works
Some specific protocols suggest 20 mg to 40 mg per kilogram of body weight, but you should stay below the 2,000 mg daily upper limit to avoid digestive issues
For procurement managers looking to secure stable inventory, finding a reliable supplier that delivers verifiable batch purity is essential